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A B S T R A C T
Tuberculosis (TB) is a priority in terms of incidence and mortality, with about 10.4 million new incident
cases and 1.8 million deaths in 2015. The End-TB strategy recently launched by the World Health
Organization in the context of the post-2015 agenda, aimed to achieve TB elimination, represents an
evolution of the previous historical strategies originally aimed to achieve TB control. Globally, the
current decline in TB incidence is rather slow at approximately 1,5% per year to reach the TB pre-
elimination phase by 2035 (A more aggressive approach based on diagnosis and treatment of latently
infected individuals has been proposed in the context of TB elimination to ensure future generations free
of TB. We describes 4 scenarios which, combined, describe the TB epidemiology in a given setting: 1) in
absence of interventions, 2) with early TB diagnosis and effective treatment, 3) with irregular TB
treatment, 4) with TB co-infected by HIV not undergoing anti-retroviral treatment. To achieve TB
Elimination, a more concerted action by funders and governments will be required for further
investments into TB prevention, detection and treatment.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idThe latest World Health Organization (WHO) 2016 global
tuberculosis (TB) report estimates that 10.4 million new TB cases
occurred worldwide in 2015, with six countries (India, Indonesia,
China, Nigeria, Pakistan, and South Africa) accounting for 60% of
the total burden.1 An estimated 1.8 million people died from TB
during 2015, of whom 0.4 million were co-infected with HIV. TB is
now the top cause of death due to infectious disease globally,
surpassing HIV and malaria.1 Despite recent advances in TB
diagnostics and investments in national TB services, the diagnosis
and notiﬁcation of TB remain sub-optimal in high TB burden
countries in Africa, Europe, and Asia. Only 6.1 million cases were
detected and reported in 2015 globally out of the 10.4 million cases
estimated by the WHO. This important 4.3 million gap is attributed
by the WHO to TB underreporting from countries with a rampant
private sector, while under-diagnosis is mainly observed in low-
income countries (where barriers to access to care still exist).1
The continuing spread of multidrug-resistant TB (MDR-TB) is
also of growing concern. The WHO estimated 480 000 new MDR-TB* Corresponding author.
E-mail address: giovannibattista.migliori@fsm.it (G.B. Migliori).
1 Rosella Centis and Lia D’Ambrosio contributed equally.
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1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).cases occurring in 2015, and 100 000 were reported to be
rifampicin-resistant TB following the roll-out of the GeneXpert
MTB/RIF assay.1 The countries with the highest MDR-TB burden –
India, China, and the Russian Federation – notiﬁed 45% of the total
number of cases (580 000) eligible for MDR-TB treatment.1 Only
20% of the estimated 580 000 cases were enrolled for second-line
treatment in 2015, highlighting that one out of ﬁve MDR-TB cases
are treated at present, while the treatment success rate remains
overall as low as 52%.1 In 2015, 22% of the existing HIV-positive TB
patients had no access to antiretroviral therapy (ART), as
recommended by the WHO. However, over 900 000 people living
with HIV started ART in the same year, including 87 000 children
under 5 years of age (e.g., 7% only of those being eligible).1
The End TB Strategy, recently launched by the WHO, represents
an evolution of the previous historical strategies originally aimed
at achieving TB control,2–7 but now focuses on achieving TB
‘elimination’. Mathematical modelling has been used extensively
to predict future TB trends and guide public health strategies. The
recent trajectory of TB incidence proposed in the WHO framework
for TB elimination is a good example of a possible (and
epidemiologically plausible) evolution of the disease from
2015 to 2050 (Figure 1).6,7 Globally, the current decline in TB
incidence is rather slow at approximately 1.5% per year.1 It isosis control to elimination: Where are we? What are the variables
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Figure 1. Projected acceleration in the decline of global tuberculosis incidence rates to target levels (from Ref. 4).
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decline in parts of Africa and Asia, an intermediate decline in
countries like China and Cambodia (around 5% per year), and a
signiﬁcant decline in low TB incidence countries. This rate of
decline needs to accelerate to a 4–5% annual decline by 2020 to
reach the ﬁrst milestone of the End TB Strategy.1
In order to move towards the TB pre-elimination phase by 2035
(deﬁned as less than 10 cases of TB per million population) and
then progress to TB elimination by 2050 (deﬁned as less than 1 case
per million population), more rapid progress is necessary, over and
above the present trends.6,7 The WHO hypothetical modelling
decline shows a different slope before and after 2015. The model
suggests that all possible efforts need to be made to utilize the
resources available today in terms of diagnostics, treatment
regimens, and public health strategies.8
The End TB Strategy is based on three main pillars (Table 1).3,4
Pillar one summarizes the main technical interventions aimed atTable 1
The End TB Strategy pillars and TB elimination priority action areas (adapted from Ref
End TB Strategy pillars and components
1. Integrated, patient-centred care and prevention A. Early diagnosis of T
contacts and high-risk
B. Treatment of all peo
C. Collaborative TB/HIV
D. Preventive treatmen
2. Bold policies and supportive systems A. Political commitme
B. Engagement of com
C. Universal health cov
quality and rational us
D. Social protection, po
3. Intensiﬁed research and innovation A. Discovery, developm
B. Research to optimiz
Priority action areas to reach TB elimination 
1. Ensure political commitment, funding, and stewardship for planning and essential
2. Address the most vulnerable and hard-to-reach groups 
3. Address special needs of migrants and cross-border issues 
4. Undertake screening for active TB and LTBI in TB contacts and selected high-risk g
5. Optimize the prevention and care of drug-resistant TB 
6. Ensure continued surveillance, programme monitoring, and evaluation and case b
7. Invest in research and new tools 
8. Support global TB prevention, care, and control 
TB, tuberculosis; LTBI, latent tuberculosis infection.
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and limitations? Is it achievable? Int J Infect Dis (2016), http://dx.dcontrolling TB, which include (1) rapid diagnosis, now achievable
with the GeneXpert MTB/RIF assay and new generation line probe
assays,9–12 (2) effective treatment with available treatment
regimens including the recent introduction of the new shorter
MDR-TB regimen,12–14 and (3) TB prevention with the new
package, which for the ﬁrst time considers the potential effects
of diagnosing and treating latent TB infection (LTBI) in high-risk
groups (a TB elimination intervention) in addition to vaccina-
tion.6,7,15 It is important to note that the present vaccination with
bacillus Calmette–Gue´rin (BCG), which the WHO recommends is
given at birth in high TB incidence countries, only confers
incomplete and time-limited protection, preventing TB meningitis
and other disseminated forms of TB.16 Thus, BCG makes only a
limited contribution to the decline in TB incidence.6,7
Another important clariﬁcation required is related to the
management of LTBI, an important intervention strategy among
eight proposed to reach TB elimination targets (Table 1).6,7 It aimss. 4 and7)
B including universal drug-susceptibility testing, and systematic screening of
 groups
ple with TB including drug-resistant TB, and patient support
 activities, and management of co-morbidities
t of persons at high risk, and vaccination against TB
nt with adequate resources for TB care and prevention
munities, civil society organizations, and public and private care providers
erage policy, and regulatory frameworks for case notiﬁcation, vital registration,
e of medicines, and infection control
verty alleviation, and actions on other determinants of TB
ent, and rapid uptake of new tools, interventions, and strategies
e implementation and impact, and promote innovations
End TB Strategy pillars and
components
 services of high quality 1. A–D
2. A–D
1. A–D
2. B–D
1. A–D
2. B–D
roups, and provide appropriate treatment 1. A, D
1. A–D
2. A–D
3. A–B
ased-data management 2. A–C
3. A–B
1–3
osis control to elimination: Where are we? What are the variables
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Table 2
Recommended treatment options for LTBI (adapted from Ref. 18)
Treatment options for LTBI
6 months isoniazid
OR 9 months isoniazid
OR 3-month regimen of weekly rifapentine plus isoniazida
OR 3–4 months isoniazid plus rifampicina
OR 3–4 months rifampicin alonea
LTBI, latent tuberculosis infection.
a Rifampicin- and rifapentine-containing regimens should be prescribed with
caution to people living with HIV who are on antiretroviral treatment, due to
potential drug–drug interactions (see also http://www.cdc.gov/mmWr/preview/
mmwrhtml/mm4909a4.htm).
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future TB cases may be generated. Whilst each individual
undergoing a complete cycle of LTBI treatment with one of the
recommended LTBI regimens (Table 2)17,18 will beneﬁt individu-
ally in terms of a reduced probability of progression to developing
active TB disease, the possibility of achieving a public health
impact will depend on the number of individuals with LTBI at risk
of progression to active TB who are correctly diagnosed and
treated.
The increase in TB decline shown in Figure 1 could hopefully
result from a combination of factors, including a full implementa-
tion of the principles of Pillar two of the End TB Strategy (universal
access and social protection among others), new regimens to treat
TB and LTBI, and hopefully a more effective TB vaccine (of which
15 are in the pipeline).1 An example of important declines almost
reaching 20% per year have been observed in Canada among Inuits,
where an aggressive programme of LTBI management has been
successfully implemented.19 In the absence of such an ‘aggressive’
approach to LTBI, and success in tackling the other priority issues
summarized in Table 1 (managing immigrants, refugees, andFigure 2. Tuberculosis transmission model: (A) in the absence of TB interventions; (B) wi
the absence of antiretroviral treatment with TB/HIV co-infection.
Please cite this article in press as: Centis R, et al. Shifting from tubercul
and limitations? Is it achievable? Int J Infect Dis (2016), http://dx.dhard-to-reach populations, MDR-TB, TB–HIV co-infection, etc.), TB
elimination will not be reached in low TB incidence countries.6,7
The current slow decline in the global TB incidence curve needs
to be viewed from a historical perspective with ﬁndings of ancient
Mycobacterium tuberculosis DNA in mammoth bones, Egyptian
mummies, and in our pre-historical ancestors.20
Karel Styblo (1921–1998) tried to describe the main epidemio-
logical and control scenarios with his famous model.21,22 A
simpliﬁed description of some of the scenarios that, in different
proportions, tend to determine the real epidemiology of TB in a
given setting is proposed below (Figure 2). In the absence of
interventions, an infectious (e.g., a sputum smear-positive) patient
infects 10 persons a year for 2 years before healing spontaneously
or dying (Figure 2A). Given a 10% lifetime probability of acquiring
disease given the infection and the 50% probability of becoming
sputum smear-positive, a case generates another case, contribut-
ing to keeping the epidemic level stable. Although, theoretically,
control interventions are present globally, situations of difﬁcult
implementation (e.g., difﬁcult access, disaster and conﬂict situa-
tions, war settings, etc.) still exist. In a scenario where rapid
diagnosis and effective treatment can be applied (Figure 2B), only
ﬁve individuals are infected and, as a result, only 0.25 cases are
generated by the original infectious case. That is similar to saying
that we need four sputum smear-positive cases to generate a new
infectious one. This shows that an adequate implementation of the
directly observed treatment short course (DOTS) strategy (as it was
known at the time it was launched) could have a substantial
impact on the epidemic in the absence of factors working in an
opposite direction, like HIV or any other factor increasing the
probability of acquiring TB disease given infection (e.g., diabetes,
stress as observed in war areas or in migrants/refugees, etc.).
If irregularities or interruptions occur during treatment (as is
the case in several settings with a high prevalence of MDR-TB), it is
sufﬁcient to prevent death and prolong the infectious period, soth early TB diagnosis and effective treatment; (C) with irregular TB treatment; (D) in
osis control to elimination: Where are we? What are the variables
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turn will gradually result in a more severe drug resistance pattern
(Figure 2C). This explains why in some countries, particularly in the
Former Soviet Union, over 18–20% of new cases and 50% of
retreatment cases harbour MDR strains of M. tuberculosis.23–26
Under the hypothetical scenario of a population with TB co-
infected by HIV not undergoing ART (Figure 2D), with a different
mechanism than in Figure 1A (e.g., on the left part of the ring, due
to the higher breakdown rate infection–diseases), one infectious
case generates another two cases, again contributing to reducing
the speed of decline. Although no country has a 100% TB/HIV co-
infection rate, there are settings with an HIV prevalence in the
general population of between 20% and 70% in speciﬁc risk groups.
Whilst a large proportion of countries are rolling out antiretrovir-
als, there are always settings where difﬁcult access or logistical
problems make it difﬁcult to cover all individuals needing them.
In summary, if the End TB Strategy is to be successful in
achieving TB elimination, a more concerted action by funders and
governments will be required for further investment in TB
prevention, detection, and treatment.
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